Friday, October 11, 2019
ADVERUM BIOTECHNOLOGIES INC (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022 intravitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the Retina Sub-specialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA.
NEXT EARNING: Nov 11, 2019
MARKET CAP: $333.254 Million
Press play on the interactive chart below to watch $ADVM’s instant replay!!
- Bullish Gartley pattern;
- Fibonacci 876 retracement is an important reversal level in high volatility trades.
- Our MS Signal oscillator indicating RSI moving higher and now being a potential good time to buy for a bounce.
- MS CCI Squeeze also indicating that bulls are re-gaining control (over mid-line suggests potential squeeze incoming).
Please like, share, and follow so I can continue finding awesome trades. Check out MS Money Trade Ideas for pre-researched trades to add to your watch-list!! Thanks in advance.
Disclosure: I am long ADVM. I may buy or sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.